Foresight Diagnostics ("Foresight") announced that it has entered into a limited licensing agreement with Roche Molecular Systems and Roche Sequencing Systems (together, "Roche") related to Foresight's patented PhasED-Seq™ technology. The agreement closes the litigation between the parties, with all claims against Foresight, its founders, and Stanford University dismissed with prejudice.

Under the terms of the agreement, Foresight has granted Roche a limited royalty-bearing non-exclusive sublicense under certain patents for use of PhasED-Seq for the development of in vitro diagnostic (IVD) kits for Non-Hodgkin's Lymphoma (NHL).

Intellectual property rights in the PhasED-Seq technology remain with Stanford University, with Foresight continuing to hold the exclusive license to the patents for all uses and geographies.

"We are pleased to have resolved our differences with Roche and to move forward with this licensing agreement, which provides Roche with tailored rights in the field of Non-Hodgkin's Lymphoma," said Jake Chabon, PhD, Chief Executive Officer of Foresight Diagnostics. "This resolution allows Foresight to remain focused on our mission to advance cutting-edge diagnostics aimed at improving outcomes for cancer patients worldwide."